Drug details

VPRIV (velaglucerase alfa for injection)

type of Enzymes, Metabolic

VPRIV (velaglucerase alfa) is an enzyme produced in a fibroblast cell line that catalyzes the hydrolysis of the glycolipid glucocerebroside to glucose and ceramide in the lysosome of macrophage cell types. VPRIV is indicated for long-term enzyme replacement therapy for pediatric and adult patients with the rare genetic disorder, type 1 Gaucher disease.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• fever,
• dizziness,
• headache,
• weakness,
• lightheadedness
• chest discomfort,
• tiredness, and

The following drugs are related to VPRIV, either as a replacement or used together:

• Cerdelga (eiglustat capsules)
• Cerezyme (imiglucerase)
• Zavesca (miglustat)